Cargando…
Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic mo...
Autores principales: | de Castro-Suárez, Niurys, Trame, Mirjam N., Ramos-Suzarte, Mayra, Dávalos, José M., Bacallao-Mendez, Raymed A., Maceo-Sinabele, Anaelys R., Mangas-Sanjuán, Víctor, Reynaldo-Fernández, Gledys, Rodríguez-Vera, Leyanis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760646/ https://www.ncbi.nlm.nih.gov/pubmed/33256255 http://dx.doi.org/10.3390/pharmaceutics12121147 |
Ejemplares similares
-
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
por: Xu, Shuping, et al.
Publicado: (2016) -
Nimotuzumab for COVID-19: case series
por: Abdo Cuza, Anselmo A, et al.
Publicado: (2021) -
Compromised Cytoarchitecture and Polarized Trafficking in Autosomal Dominant Polycystic Kidney Disease Cells
por: Charron, Audra J., et al.
Publicado: (2000) -
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022) -
Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease
por: Leierer, Johannes, et al.
Publicado: (2021)